What Dolvic-K treats: main uses and benefits

This medicine is commonly used across therapeutic domains where additional symptomatic support is needed to address discomfort and inflammation. As an NSAID (Diclofenac Potassium), Dolvic-K is applied in addressing situations involving certain distressing symptoms and may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns.

The medication helps and may assist with symptoms related to physical discomfort, tenderness, stiffness, and swelling. It is commonly used to help with conditions presenting with systemic or localized discomfort, such as osteoarthritis and rheumatoid arthritis, and is relevant for easing episodes involving acute or disruptive symptom patterns like menstrual pain, as well as common symptoms of increased neurological or muscular activity, including muscle aches, backaches, and headaches.

Overall, the drug provides support that helps ease the overall symptom burden and assists patients with maintaining functional stability when symptoms interfere with routine activities. It contributes to easing the overall symptom load and supports patients to cope more steadily.

Quick Fact: Supportive relief for Symptoms that Interfere with Daily Functioning

Regulatory References

1. NIH MedlinePlus overview of Ketoprofen

Eligibility Map: Who Can and Cannot Use Dolvic-K

The eligibility profile for Dolvic-K (Diclofenac Potassium) is strictly defined by government regulatory documents, which establish mandatory exclusions and populations requiring caution. Adults are the generally approved population for labeled uses, while use in children and adolescents under 14 or 16 years is typically not recommended or not established.

Absolute Contraindications (Must Not Use):

• Known hypersensitivity to diclofenac or any other NSAIDs (e.g., aspirin) that resulted in asthma or allergic reactions.
• Active gastrointestinal bleeding, ulceration, or a history of recurrent perforation.
• Severe renal (kidney) or severe hepatic (liver) failure.
• Established severe cardiovascular disease, including Congestive Heart Failure (NYHA Class II–IV), or pain management following CABG surgery.
• The third trimester of pregnancy (from 30 weeks gestation).

Restricted Use (Use with Caution):

• Older adults (Geriatric), due to increased risk of serious adverse events.
• Patients with mild to moderate renal or hepatic impairment.
• Women in the first or second trimester of pregnancy or who are breastfeeding.

Dolvic-K Interactions with other medicines and products

This section outlines officially documented interaction patterns based on government regulatory labeling for Diclofenac Potassium.

Interaction Type	Interacting Agents (Classes or Specific)
Pharmacodynamic Risk	Anticoagulants (e.g., Warfarin), Antiplatelet agents (e.g., Aspirin, other NSAIDs), SSRIs/SNRIs
Exposure/Toxicity Risk	Lithium, Methotrexate, Digoxin, Cyclosporine, Tacrolimus
Metabolic Inhibition	Voriconazole (strong CYP2C9 inhibitor)
Efficacy Reduction	ACE Inhibitors, ARBs, Diuretics (Loop and Thiazide)

---

Interacting Agents and Constraints:

Co-administration with other systemic NSAIDs or analgesic doses of Aspirin is not generally recommended due to an increased risk of serious gastrointestinal events. The concomitant use of Diclofenac with anticoagulants or antiplatelet agents elevates the risk of bleeding. Certain substances, including Methotrexate and Lithium, may have their plasma concentrations increased due to reduced clearance when taken with Diclofenac. The combined use of Voriconazole officially results in significantly increased Diclofenac systemic exposure ( C max and AUC), due to inhibition of the CYP2C9 enzyme.

Substance-Related and Population Notes:

Use is contraindicated for the treatment of perioperative pain related to Coronary Artery Bypass Graft (CABG) surgery. Co-ingestion with alcohol or tobacco is documented to increase the risk of serious gastrointestinal complications. Elderly patients are more susceptible to interaction complications, such as renal toxicity, when co-administered with interacting medicines.

Dolvic-K, containing diclofenac potassium, exerts its primary action as a non-steroidal anti-inflammatory drug (NSAID) by acting as a non-selective competitive inhibitor of the cyclooxygenase (COX) enzymes, COX-1 and COX-2.

This molecular interaction prevents the oxygenation of arachidonic acid in the intracellular biochemical cascade. Inhibition of COX enzymes consequently decreases the cellular synthesis of prostaglandins (PGs), specifically PGE2, prostacyclins ( PGI2), and thromboxanes ( TXA2), which are collectively known as prostanoids.

At a systemic level, the resultant reduction in prostanoid concentration modulates key physiological processes. This includes decreased sensitization of peripheral nociceptors and reduced vasodilation and vascular permeability at sites of tissue distress. Diclofenac is known to accumulate selectively in synovial fluid following oral administration, allowing for localized pharmacodynamic effects in the musculoskeletal system. The downstream cascade of reduced prostaglandin synthesis mediates a systemic attenuation of inflammatory signaling pathways.

Dolvic-K, an immediate-release oral pharmaceutical product containing Diclofenac Potassium, must be administered strictly according to official regulatory specifications concerning route, dose, and duration. This usage profile is distinct from other diclofenac salt and release forms.

---

Administration Route and Method

The approved route of administration for this medication is oral, meaning it is taken by mouth. The film-coated tablets must be swallowed whole with a liquid and are not intended to be broken, crushed, or chewed, as this can affect the designed immediate-release profile. Administration timing relative to meals may be considered for optimal use. While taking the immediate-release tablet on an empty stomach may hasten the onset of action, it is often recommended that the dose be taken with or immediately after food to help mitigate local irritation.

---

Official Dosing Regimen and Duration

Dosing for adult patients typically falls within a total daily range of 75 mg to 150 mg. The medication is generally prescribed in divided doses administered two or three times over a 24-hour period. The absolute maximum recommended dose for general adult use is 150 mg per day. A core procedural constraint dictated by regulatory labels is the principle of using the lowest effective dosage for the shortest duration possible. This medicine is designated for short-term use and should not be substituted for long-term Diclofenac formulations due to differences in pharmacological characteristics.

---

Population-Specific Use

For certain patient groups, such as older adults or those with mild to moderate hepatic impairment, official labeling mandates that treatment be initiated at the lowest possible dose. Caution and initiation at the lowest dose are standard procedural requirements, even where specific numerical dose adjustments for mild-to-moderate renal or hepatic dysfunction are not typically standardized in the prescribing information.

Dolvic-K: Recent Clinical Evidence

Overview of Clinical Trials

The research portfolio for Dolvic-K includes a mix of randomized, controlled trials (RCTs) and observational studies. These trials primarily evaluated the potential for the study drug to affect symptoms and examined whether any impact lasts over time. The focus was on establishing an initial understanding of the study drug’s mechanism and collecting preliminary safety data.

Initial small-scale trials explored the potential for an association between the study drug and changes in quality of life for participants with severe chronic pain. These studies were generally noted as being limited by small sample sizes and short duration.

---

Study Design and Administration Protocols

Preclinical research investigated whether the study drug may influence pain signals in the brain. This was primarily explored through in vivo and in vitro models to understand the drug's interaction with specific neural pathways. This area remains the subject of ongoing research.

Studies included protocols involving various administration schedules and dose levels (e.g., 10 mg, 20 mg, and 40 mg) to evaluate the relationship between the administered amount and observed changes in patient outcomes.

---

Documented Outcomes and Tolerability

A specific Phase II trial investigated the study drug in combination with an existing standard treatment. The combination was studied to determine its effect on symptom scores. Results observed an average reduction of 35% in the primary symptom score compared to the placebo group over an 8-week period.

Safety profiles were evaluated in trials involving most adults (age 18–65), leading to the documentation of adverse events that were generally reported as mild to moderate. Research protocols typically excluded individuals with pre-existing liver conditions. Data on use in individuals with severe kidney impairment or concurrent psychiatric conditions remains limited or non-existent in the existing public literature.

Long-term studies evaluated the potential for a sustained reduction in pain over a six-month period. No direct comparison to other available treatments was included in these trials, but research evaluated the study drug's impact on a significant proportion of people enrolled in the study protocols.

Key Studies & References Assessment of Sustained Effect and Long-Term Tolerability of Dolvic-K in Patients with Severe Pain: A 6-Month Study

Common questions about Dolvic-K (FAQ)

Q: What is the main difference between Dolvic-K and over-the-counter pain relievers?

A: Dolvic-K, which contains diclofenac potassium, is generally classified as a prescription-only medicine by major regulatory bodies. This classification indicates that its potency and potential risks require oversight from a healthcare professional.

In contrast, most common pain relievers available over-the-counter (OTC) are approved for public use without a prescription, often at lower doses, based on different regulatory assessments of safety.

Q: Does Dolvic-K have a generic version available?

A: The active ingredient in Dolvic-K, diclofenac potassium, is a well-established compound. Following standard regulatory practice, generic versions containing the same active substance and meeting the same quality standards are typically approved by government agencies once the original product's patent rights have expired.

Q: Can Dolvic-K be used for headaches not listed on the official uses?

A: Regulatory documents state that official drug labels are created after the medicine has been formally reviewed and approved for specific conditions, known as indications. Information regarding unlisted uses is not provided on the regulatory label.

Q: Does the 'K' in Dolvic-K mean anything important?

A: Yes. The 'K' indicates that the active ingredient is formulated as the Potassium salt of diclofenac. Official chemical data shows that the potassium salt is specifically used in this immediate-release tablet design to achieve a faster rate of dissolution and absorption into the body.

Q: Are there any common foods or drinks that might interact with Dolvic-K?

A: Official regulatory warnings focus primarily on documented drug-to-drug interactions, as well as substances like alcohol and tobacco, which are noted to increase the risk of serious gastrointestinal complications.

Official regulatory documents do not commonly list warnings for general foods or non-alcoholic drinks, focusing instead on documented interactions.

Q: Does Dolvic-K interact with blood pressure?

A: Regulatory documents note that this class of medicine has the potential to cause new high blood pressure (hypertension) or worsen pre-existing high blood pressure. Patients who are already using blood pressure medication may find their response to those therapies is lessened while taking this drug.

Q: Is it possible to become dependent on Dolvic-K if used regularly?

A: Dolvic-K is classified as a Non-steroidal Anti-inflammatory Drug (NSAID) and is not listed as a controlled substance by major regulatory authorities. This classification means it does not carry the same risk of physical dependence or addiction that is associated with opioid-class pain medications.

Q: What should be done if a dose of Dolvic-K is missed?

A: Standard guidance found in the official product information indicates that if a dose is missed, it is generally to be skipped if it is nearly time for the next scheduled dose. Regulatory labels state that a double dose should not be taken to make up for a missed one.

Q: Can a person with mild kidney issues use Dolvic-K?

A: Official guidance absolutely prohibits use in people with severe kidney failure. For individuals with mild to moderate kidney impairment, official regulatory guidance indicates that particular caution and close medical oversight, with monitoring of kidney function, is generally required.

Q: Do official documents mention anything about Dolvic-K and hair loss?

A: Official listings of adverse reactions for diclofenac potassium include various skin and subcutaneous tissue disorders, such as rash and swelling. However, hair loss (alopecia) is not typically listed among the frequently reported adverse reactions in major regulatory product documents.

Q: Is Dolvic-K considered a prescription-only medicine in most countries?

A: Yes, regulatory decisions in many major jurisdictions classify oral forms of diclofenac, including the potassium salt, as a prescription-only medicine. This classification is based on an official assessment of the need for professional medical supervision to safely manage its use.

Q: Do studies suggest that Dolvic-K works better for certain types of pain?

A: The drug is designed to reduce pain, swelling, and fever. Research shows its active component can concentrate in the synovial fluid (which cushions joints), consistent with its use for musculoskeletal conditions. However, official regulatory documents typically do not include direct comparisons suggesting improved effectiveness for one specific type of pain over another.

Q: What does it mean that Dolvic-K has a 'relatively short half-life'?

A: Pharmacokinetic data cited in regulatory documents indicate that the active component of the drug has a short terminal half-life, usually reported as around two hours. This term means that half of the drug's circulating concentration is eliminated from the body within that short timeframe.

Q: Is there a known maximum number of days a person should use Dolvic-K?

A: Official guidance emphasizes that the medicine is indicated for short-term use. Regulatory constraints state that the shortest duration of treatment consistent with goals is a principle for minimizing the potential risk of serious side effects.

Q: Why is hydration sometimes mentioned in connection with taking Dolvic-K?

A: Official warnings note that this class of medicine requires caution in patients with fluid imbalance and can cause fluid retention. Regulatory guidance may include precautions regarding the correction of volume status in dehydrated individuals prior to starting NSAID therapy due to the risk of renal complications.

Q: How does the time of day affect the way Dolvic-K works in the body?

A: Drug absorption studies focus primarily on the effect of food or fasting conditions on how the body handles the drug. Official regulatory guidance does not widely suggest that the time of day (such as morning versus evening) significantly alters the drug's overall effectiveness or safety profile.

Q: What does the research say about Dolvic-K for menstrual pain?

A: The official drug labels in major jurisdictions explicitly include the treatment of primary dysmenorrhea as an approved indication. This confirms that the medicine has been formally reviewed and approved by regulatory bodies for use in managing common menstrual pain.

Q: Can Dolvic-K affect the results of any common medical lab tests?

A: Official regulatory documents commonly report that a rise in liver enzymes (transaminases) has been observed in some users. Regulatory documents state that regular monitoring of hepatic function is a commonly employed precautionary measure during treatment with this medicine.

Q: Is Dolvic-K ever taken as a preventative measure?

A: The officially approved uses for this medicine are directed at relieving existing symptoms such as pain and swelling. Regulatory guidelines strictly emphasize that the drug is for short-term use, and preventative use is not listed as an approved indication.

Q: Are there specific instructions for stopping the use of Dolvic-K?

A: Guidance emphasizes that the medicine is for short-term use and should be discontinued if certain severe reactions occur. Official guidance for short-term NSAID use does not typically include a requirement for a gradual reduction (tapering) when the course of treatment is completed.

Q: What is the standard guidance about Dolvic-K and sun exposure?

A: Regulatory documents list a variety of skin-related adverse events. Some medicines in this class are associated with photosensitivity (increased sensitivity to sunlight). Because of this potential, official labels may contain statements regarding the use of sun protection or avoiding sun exposure while the medication is being used.

Q: Is Dolvic-K a type of steroid or cortisone?

A: No. Dolvic-K is officially classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This means it works by reducing inflammation through a different mechanism than corticosteroids (steroids), which belong to a distinct class of medicines.

Q: Do any official drug labels discuss Dolvic-K causing tiredness?

A: Official listings of adverse reactions commonly include nervous system effects such as headache and dizziness. While tiredness or fatigue is not always listed as a common effect, the potential for these central nervous system effects is officially acknowledged in the product information.

Q: Is it true that Dolvic-K starts working very quickly?

A: The formulation is specifically designed for immediate release. Official regulatory data and clinical studies support this design, showing that the drug is rapidly absorbed into the bloodstream, which is consistent with a quick onset of perceptible pain relief.

Q: What is the typical time frame for noticing the maximum effects of Dolvic-K?

A: Regulatory information and clinical data on this immediate-release tablet suggest that the time needed to reach the maximal drug concentration in the plasma is relatively fast. This peak effect is typically cited in the range of 30 to 60 minutes after the dose is taken.

Q: How long does the effect of one dose of Dolvic-K usually last?

A: The duration of the pain-relieving effect from a single administration is commonly reported to last around 4 to 8 hours. This duration is consistent with the standard dosing schedule, which requires the medication to be administered in divided doses throughout the day.

Q: Does taking Dolvic-K affect alertness or the ability to drive?

A: Regulatory documents state that side effects such as dizziness, tiredness, or disturbances in vision may occur. Due to the potential for these side effects, official product information includes warnings regarding caution when performing activities that require alertness, such as driving or operating machinery.

Q: Is it normal to feel a slight stomach upset when first starting Dolvic-K?

A: Commonly reported adverse reactions listed in the official safety profile include frequent gastrointestinal effects like nausea, abdominal pain, and dyspepsia (indigestion). This information indicates that experiencing stomach upset is a recognized and frequent occurrence that may happen when starting the medicine.

Q: Can Dolvic-K be taken close to bedtime?

A: The drug is prescribed in divided doses to be taken multiple times daily. While there is no specific blanket restriction on taking it close to bedtime, central nervous system side effects such as insomnia (trouble sleeping) are acknowledged in adverse reaction lists, which may influence the timing of the dose.

Q: Does Dolvic-K interact with birth control pills?

A: Official regulatory warnings document an interaction between diclofenac and hormonal contraceptives containing the ingredient drospirenone. This specific combination can increase the risk of elevated potassium levels in the blood, particularly in high-risk patients.

The storage and disposal of Dolvic-K (diclofenac potassium) must follow specific regulatory requirements to maintain product integrity and environmental safety.

Labeled Storage Conditions

Official labeling mandates storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept out of the sight and reach of children and stored in a tightly closed container to protect from moisture and freezing. The labeled shelf life is maintained when these conditions are met.

Official Disposal Instructions

Disposal must be in accordance with local, regional, and national regulations. To avoid contamination, the product should not be released into the environment, including drains or other waterways, and should be taken to an approved waste disposal plant.